How to optimize the treatment of early stage Parkinson's disease

Research output: Contribution to journalArticle

Abstract

The approach to early Parkinson's disease denotes the communication of the diagnosis and important decisions, such as when and how to start treatment. Evidence based medicine and guidelines indicate which drugs have robust evidence of efficacy and tolerability in this specific population. However, de-novo patients may show different characteristics and they may be in a different phase of their disease. In this review, we will give an insight into the appropriate time therapy should be started and the actual knowledge about disease modification therapies. Moreover, the drugs indicated for early treatment will be considered and an indication for the use of these drugs will be given with the support of the actual knowledge.

Original languageEnglish
Article number4
JournalTranslational Neurodegeneration
Volume4
Issue number1
DOIs
Publication statusPublished - Feb 25 2015

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Cognitive Neuroscience

Cite this